{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Number of participants positive to anti-cetrelimab antibodies was reported using validated immunoassay for anti-drug antibody (ADA) analysis.","groups":[{"description":"Participants with CIS with or without papillary disease, received TAR-200 intravesically every 3 weeks (Q3W) from Week 0 for the first 24 weeks, followed by every 12 weeks (Q12W) dosing through Week 99 in combination with cetrelimab 360 milligrams (mg) intravenously (IV) Q3W from Week 0 through Week 78. TAR-200 was inserted intravesically via the urinary placement catheter (UPC).","id":"OG000","title":"Cohort 1: TAR-200 + Cetrelimab (CIS With or Without Papillary Disease)"},{"description":"Participants with CIS with or without papillary disease, received cetrelimab 360 mg IV Q3W from Week 0 through Week 78.","id":"OG001","title":"Cohort 3: Cetrelimab IV Monotherapy (CIS With or Without Papillary Disease)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"FAS included all enrolled participants who received at least 1 dose of study treatment. Here \"N\" (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure. This OM was planned to be analyzed for Cohorts 1 and 3 only.","reportingStatus":"POSTED","timeFrame":"From date of first dose up to clinical cut-off date 3rd July 2025 (54 months)","title":"Cohorts 1 and 3: Number of Participants With Anti-cetrelimab Antibodies","type":"SECONDARY","unitOfMeasure":"Participants"}